Michael O'Neill is currently the Executive Director of Drug Discovery at AbbVie, where they lead the Neuroscience Drug Discovery Department in Ludwigshafen, Germany, focusing on the development of therapeutics for Alzheimer's Disease, Parkinson's Disease, and related neurodegenerative conditions. Previously, O'Neill held various roles at Eli Lilly and Company, including Senior Director of Biology Drug Discovery, overseeing large teams and leading multi-site projects aimed at treating neurodegenerative diseases. O’Neill earned a PhD in Pharmacology and a BSc in Biochemistry from the University of Galway.
This person is not in the org chart
This person is not in any teams
This person is not in any offices